Essity to acquire feminine care business from Kenvue in Brazil

0
2

Essity has agreed to acquire Kenvue’s feminine care business in Brazil for USD 284 million, approximately SEK 2.7 billion, strengthening its position in the country and reinforcing its leadership in feminine care across Latin America.

The transaction, structured as an asset purchase from certain Kenvue subsidiaries, includes the Carefree, Sempre Livre and o.b. brands for sanitary pads, pantyliners and tampons, as well as related manufacturing equipment in Brazil. For the 12 months ending June 30, 2026, the business generated net sales of approximately BRL 800 million, equivalent to around SEK 1.4 billion, with good profitability.

“With this acquisition we establish a strong position in feminine care in Brazil and it marks another step in our strategy to grow in our most value-creating categories,” said Ulrika Kolsrud, President and CEO of Essity. “Brazil represents a significant growth opportunity in hygiene and health, where we already hold a leading position in incontinence products.”

The acquisition is subject to regulatory approval in Brazil and other customary closing conditions. It also depends on the completion of the planned Kimberly-Clark and Kenvue transaction. Closing is currently expected during the second quarter of 2027.

The deal further expands Essity’s presence in feminine care, where the company offers sanitary pads, liners, tampons, intimate soaps, intimate wipes and leakproof apparel under brands including Libresse, Bodyform, Nana, Saba, Libra and Nosotras. In February 2026, Essity completed the acquisition of the Carefree, Stayfree and o.b. brands in North America from Edgewell Personal Care.

Brazil is the fourth-largest feminine care market globally and one of the world’s largest hygiene markets. Essity already has a strong presence in the country through its TENA incontinence business, including a production facility in Jarinu, as well as its Professional Hygiene and Medical Solutions operations.

LEAVE A REPLY

Please enter your comment!
Please enter your name here